Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 3 of 4 for:    KHK4083

Study of a Monoclonal Antibody KHK4083 in Moderate Ulcerative Colitis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02647866
Recruitment Status : Completed
First Posted : January 6, 2016
Results First Posted : March 5, 2020
Last Update Posted : March 5, 2020
Sponsor:
Information provided by (Responsible Party):
Kyowa Kirin, Inc.

Tracking Information
First Submitted Date  ICMJE December 8, 2015
First Posted Date  ICMJE January 6, 2016
Results First Submitted Date  ICMJE January 9, 2020
Results First Posted Date  ICMJE March 5, 2020
Last Update Posted Date March 5, 2020
Actual Study Start Date  ICMJE June 2016
Actual Primary Completion Date September 2018   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: February 21, 2020)
  • Number of Subjects With Treatment-related Adverse Events [ Time Frame: Up to 52 weeks ]
    To determine the safety and tolerability of KHK4083
  • Number of Subjects With Treatment-related Serious Adverse Events [ Time Frame: Up to 52 weeks ]
    To determine the safety and tolerability of KHK4083
  • Number of Subjects Who Show Improvement in the Mucosa at Week 12 [ Time Frame: 12 weeks ]
    Measured by the modified Mayo endoscopy sub-score (mMES), which ranges from 0-3 with higher scores = more severe disease.
  • Proportion of Subjects Who Show Improvement in the Mucosa at Week 52 [ Time Frame: 52 weeks ]
    Measured by the modified Mayo endoscopy sub-score (mMES), which ranges from 0-3 with higher scores = more severe disease.
Original Primary Outcome Measures  ICMJE
 (submitted: January 5, 2016)
  • Proportion of subjects with treatment-related adverse events [ Time Frame: Up to 52 weeks ]
    To determine the safety and tolerability of KHK4083
  • Proportion of subjects with treatment-related serious adverse events [ Time Frame: Up to 52 weeks ]
    To determine the safety and tolerability of KHK4083
  • Proportion of subjects who show improvement in the mucosa at Week 12 [ Time Frame: 12 weeks ]
    Measured by the modified Mayo endoscopy sub-score (mMES)
  • Proportion of subjects who show improvement in the mucosa at Week 52 [ Time Frame: 52 weeks ]
    Measured by the modified Mayo endoscopy sub-score (mMES)
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: February 21, 2020)
  • Number of Subjects With Confirmed Anti-KHK4083 Antibodies (Immunogenicity) [ Time Frame: 52 weeks ]
    The immunogenicity was assessed by determination of the development of anti-drug antibodies (ADA) against KHK4083.
  • Number of Subjects Who Achieve Mucosal Healing at Week 12 [ Time Frame: 12 weeks ]
    The endoscopic Mayo Score (Mayo endoscopic subscore) evaluates ulcerative colitis stage, based only on endoscopic exploration. The scale ranges from 0 to 3, with higher scores = more severe activity. Mucosal healing is defined as modified Mayo endoscopy sub-score (mMES) of 0 or 1 at Week 12.
  • Number of Subjects Who Achieve Mucosal Healing at Week 52 [ Time Frame: 52 weeks ]
    The endoscopic Mayo Score (Mayo endoscopic subscore) evaluates ulcerative colitis stage, based only on endoscopic exploration. The scale ranges from 0 to 3, with higher scores = more severe activity. Mucosal healing is defined as modified Mayo endoscopy sub-score (mMES) of 0 or 1.
  • Number of Subjects Who Achieve Clinical Improvement at Week 12 [ Time Frame: 12 weeks ]
    The Mayo Clinic Score is comprised of 4 parts: stool frequency, rectal bleeding, endoscopic findings and physician's global assessment, each scored from 0-3. The total score ranges from 0-12 with higher scores indicating increased severity of disease. Improvement will be based on a reduction in the total Mayo Clinic score.
  • Change From Baseline in Total Mayo Scale Score at Week 52 [ Time Frame: 52 weeks ]
    The Mayo Clinic Score is comprised of 4 parts: stool frequency, rectal bleeding, endoscopic findings and physician's global assessment, each scored from 0-3. The total score ranges from 0-12 with higher scores indicating increased severity of disease. Improvement was based on a reduction (mean change from Baseline [Week 0] to Week 52) in the total Mayo Clinic score.
  • Number of Subjects Who Achieve a Clinical Response at Week 12 [ Time Frame: 12 weeks ]
    The Mayo Clinic Score is comprised of 4 parts: stool frequency, rectal bleeding, endoscopic findings and physician's global assessment, each scored from 0-3. The total score ranges from 0-12 with higher scores indicating increased severity of disease. Clinical Response is a reduction in the total Mayo Clinic score of at least 3 points.
  • Number of Subjects Who Achieve a Clinical Response at Week 52 [ Time Frame: 52 weeks ]
    The Mayo Clinic Score is comprised of 4 parts: stool frequency, rectal bleeding, endoscopic findings and physician's global assessment, each scored from 0-3. The total score ranges from 0-12 with higher scores indicating increased severity of disease. Clinical Response indicates the change from Baseline in the Total Mayo Clinic score <= -3 and the percentage change from Baseline in the Total Mayo Clinic score <= -30% to Week 12, with an accompanying decrease in the rectal bleeding subscore of at least 1 point or an absolute rectal bleeding subscore of <= 1.
  • Number of Subjects Who Achieve Clinical Remission at Week 12 [ Time Frame: 12 weeks ]
    The Mayo Clinic Score is comprised of 4 parts: stool frequency, rectal bleeding, endoscopic findings and physician's global assessment, each scored from 0-3. The total score ranges from 0-12 with higher scores indicating increased severity of disease. Clinical remission is defined as a total Mayo Clinic score of ≤ 2 and no subscores > 1.
  • Number of Subjects Who Achieve Clinical Remission at Week 52 [ Time Frame: 52 weeks ]
    The Mayo Clinic Score is comprised of 4 parts: stool frequency, rectal bleeding, endoscopic findings and physician's global assessment, each scored from 0-3. The total score ranges from 0-12 with higher scores indicating increased severity of disease. Clinical remission is defined as a total Mayo Clinic score of ≤ 2 and no subscores > 1.
Original Secondary Outcome Measures  ICMJE
 (submitted: January 5, 2016)
  • Proportion of subjects with confirmed anti-KHK4083 antibodies (immunogenicity) [ Time Frame: 52 weeks ]
  • Proportion of subjects who achieve mucosal healing at Week 12 [ Time Frame: 12 weeks ]
    Mucosal healing is defined as modified Mayo endoscopy sub-score (mMES) of 0 or 1
  • Proportion of subjects who achieve mucosal healing at Week 52 [ Time Frame: 52 weeks ]
    Mucosal healing is defined as modified Mayo endoscopy sub-score (mMES) of 0 or 1
  • Proportion of subjects who achieve clinical improvement at Week 12 [ Time Frame: 12 weeks ]
    Improvement will be based on a reduction in the total Mayo Clinic score (0 to 12).
  • Proportion of subjects who achieve clinical improvement at Week 52 [ Time Frame: 52 weeks ]
    Improvement will be based on a reduction in the total Mayo Clinic score (0 to 12).
  • Proportion of subjects who achieve a clinical response at Week 12 [ Time Frame: 12 weeks ]
    Reduction in the total Mayo Clinic score of at least 3 points
  • Proportion of subjects who achieve a clinical response at Week 52 [ Time Frame: 52 weeks ]
    Reduction in the total Mayo Clinic score of at least 3 points
  • Proportion of subjects who achieve clinical remission at Week 12 [ Time Frame: 12 weeks ]
    Clinical remission is defined as a total Mayo Clinic score of ≤ 2 and no subscores > 1
  • Proportion of subjects who achieve clinical remission at Week 52 [ Time Frame: 52 weeks ]
    Clinical remission is defined as a total Mayo Clinic score of ≤ 2 and no subscores > 1
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Study of a Monoclonal Antibody KHK4083 in Moderate Ulcerative Colitis
Official Title  ICMJE A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Multiple Ascending Dose Study (Induction Therapy) & Long-term Extension Therapy of an Anti-OX40 Monoclonal Antibody (KHK4083) in Subjects With Moderately Active UC
Brief Summary The purpose of this study is to determine the safety and tolerability of administration of multiple ascending doses of KHK4083 and to select the highest dose tolerated by subjects with moderately active Ulcerative Colitis (UC) followed by a Long-term Extension Therapy (LTE) phase for eligible subjects with a clinical response.
Detailed Description

A Phase 2, double-blind clinical study of multiple ascending doses of KHK4083 (or placebo) with an Long-term Extension Therapy (LTE) phase will be conducted in approximately 60 randomized adult subjects with moderately active UC who have a documented unsuccessful previous treatment.

The Treatment Period includes double-blind Induction Therapy (12 weeks) and Open-label Therapy (OLE) phase (40 weeks) for eligible subjects at Week 12. Subjects already enrolled in the double-blind, long-term extension (LTE) under preceding versions of the protocol who worsen may be eligible to transition to the OLE up to Week 28.

The Follow Up Period after the last administration will be for up to 16 weeks.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Sequential Assignment
Intervention Model Description:

Double-blind Induction Therapy was separated into Part A for administration of multiple ascending IV doses of KHK4083 (or placebo) to subjects in Cohorts 1-3 and Part B for administration of the maximally tolerated dose (as determined in cohorts 1-3) in expansion cohort 4. Subjects in Part A were prohibited from participating in Part B.

Subjects in each cohort were randomly assigned in a 3:1 ratio to receive KHK4083 or placebo by IV infusion over 60 minutes (± 10 min.). Each subject received a total of 6 treatments (1 IV infusion per treatment) every 2 weeks from Week 0 (Day 1) to Week 10.

Subjects who completed double-blind Induction Therapy (i.e., at least 5 of 6 treatments) and had a clinical response or mucosal healing, as defined above, were eligible to continue in double-blind Long Term Extension Therapy (Weeks 12-52) & after protocol amendment all subjects who received at least 5 of 6 treatments were eligible for Open Label Extension Therapy (Weeks 12-52).

Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Condition  ICMJE
  • Ulcerative Colitis
  • Digestive System Diseases
  • Colitis, Ulcerative
  • Colitis
  • Gastrointestinal Diseases
  • Inflammatory Bowel Diseases
  • Intestinal Diseases
  • Colonic Diseases
  • Autoimmune Disease
  • Abdominal Pain
Intervention  ICMJE
  • Drug: KHK4083
    IV Infusion
  • Drug: Placebo
    IV Infusion
Study Arms  ICMJE
  • Experimental: KHK4083 Cohort 1
    Subjects received one 1.0 mg/kg IV infusion treatment of KHK4083 every two weeks from Week 0 to Week 10 of Induction Therapy. Subjects who chose to continue into extension therapy and were eligible received one IV infusion every 4 weeks (at the same dose as Induction Therapy) from Week 12 to Week 48.
    Intervention: Drug: KHK4083
  • Experimental: KHK4083 Cohort 2
    Subjects received one 3.0 mg/kg IV infusion treatment of KHK4083 every two weeks from Week 0 to Week 10 of Induction Therapy. Subjects who chose to continue into extension therapy and were eligible received one IV infusion every 4 weeks (at the same dose as Induction Therapy) from Week 12 to Week 48.
    Intervention: Drug: KHK4083
  • Experimental: KHK4083 Cohort 3
    Subjects received one 10.0 mg/kg IV infusion treatment of KHK4083 every two weeks from Week 0 to Week 10 of Induction Therapy. Subjects who chose to continue into extension therapy and were eligible received one IV infusion every 4 weeks (at the same dose as Induction Therapy) from Week 12 to Week 48.
    Intervention: Drug: KHK4083
  • Experimental: KHK4083 Cohort 4
    Subjects received one maximum tolerated dose (10.0 mg/kg) IV infusion treatment of KHK4083 every two weeks from Week 0 to Week 10 of Induction Therapy. Subjects who chose to continue into extension therapy and were eligible received one IV infusion every 4 weeks (at the same dose as Induction Therapy) from Week 12 to Week 48.
    Intervention: Drug: KHK4083
  • Placebo Comparator: Placebo
    Subjects received one IV infusion treatment of Placebo every two weeks from Week 0 to Week 10 of Induction Therapy. Subjects who chose to continue into extension therapy and were eligible received one IV infusion every 4 weeks (at the same dose as Induction Therapy) from Week 12 to Week 48. Subjects who participated in Open-Label Therapy received KHK4083 instead of placebo.
    Intervention: Drug: Placebo
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: February 22, 2019)
66
Original Estimated Enrollment  ICMJE
 (submitted: January 5, 2016)
60
Actual Study Completion Date  ICMJE October 2018
Actual Primary Completion Date September 2018   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. Subject is able and willing to comply with study procedures, and to adhere to dosing, visit schedules and follow-up procedures as described in the protocol and ICF;
  2. Subject voluntarily signs/dates an Institutional Review Board (IRB)/Independent Ethics Committee (IEC)-approved ICF in accordance with regulatory and Institutional Guidelines;
  3. Male and female subjects ≥ 18 years of age at the time of enrollment;
  4. Subject has UC that was diagnosed at least 6 months prior to the Screening visit;
  5. Subject has moderately active UC with a total Mayo score of 4-9 and an endoscopic sub-score of at least 2, with disease that extends at least 15 cm from the anal verge;
  6. Subject has had previous treatment (within 5 years prior to Screening) with one or more of the following: corticosteroids, immunosuppressive medications or TNF antagonist therapy that was unsuccessful because of a lack of efficacy response.
  7. Female subjects (WOCBP) must have a negative pregnancy test at Screening and Baseline. WOCBP must agree to use effective contraception;
  8. Male subjects (including those who have had a vasectomy) must use adequate contraception during the study and for at least 6 months after the last dose of investigational product.

Exclusion Criteria:

  1. Subject, who, for any reason, is judged by the Investigator to be inappropriate for this study;
  2. Subject has a medical history of other clinically significant diseases/disorders;
  3. Two or more biologic treatments with different mechanisms of action (e.g., infliximab, vedolizumab and golimumab) or Three or more anti-TNF biologics e.g. infliximab, adalimumab
  4. Subject requires prescription treatment for UC, except for the stable, oral treatment of UC for 4 weeks prior to screening.
  5. Subject has received any of the following prior treatments or treatments within the specified time prior to the Baseline visit:

    • Natalizumab, efalizumab, rituximab or other lymphocyte-depleting treatments, including but not limited, to alkylating agents (such as cyclophosphamide or chlorambucil) and total lymphoid irradiation at any time;
    • TNF antagonists within 8 weeks, or 5 half-lives (up to 12 weeks);
    • Vedolizumab within 16 weeks;
    • Methotrexate, cyclosporine, mycophenolate, tacrolimus, thalidomide, or other immune altering drugs within 4 weeks (ophthalmologic preparations are permitted);
    • 5-ASA enema, steroid enema or suppository use within 2 weeks ; and/or Investigational agents within 8 weeks or 5 half-lives (whichever is longer).
  6. Subject with recent, suspected or confirmed symptomatic stenosis of the colon, abdominal abscess, or ischemic colitis based on clinical or radiographic data; a history of toxic megacolon; or who had any previous surgery for UC;
  7. Subject with known colonic dysplasia, adenomas or polyposis;
  8. Subject had major surgery within 4 weeks prior to Screening or an anticipated requirement for major surgery;
  9. Subject with enteric pathogens (including Clostridium difficile);
  10. Subject with any of the following hematological and chemistry laboratory values:

    • Platelet count < 100,000/mm3;
    • Neutrophils < 1500/mm3;
    • Serum creatinine ≥ 1.6 mg/dL (≥ 144.4 μmol/L);
    • Alkaline phosphatase > 3 times the upper limit of normal (ULN);
    • AST or ALT > 2 times ULN;
    • Total bilirubin > 2 mg/dL, unless due to Gilbert's Syndrome;
    • Serum albumin < 3 g/dL;
    • Hemoglobin < 9 g/dL;
    • Glycated serum hemoglobin A1c ≥ 9%.
  11. Subject has clinically significant cardiac disease;
  12. Subject is pregnant or breastfeeding;
  13. Subject has had major immunologic reaction;
  14. Subject is Hepatitis B core antibody or surface antigen positive and/or Hepatitis C antibody positive with detectable RNA;
  15. Subject has a history of human immunodeficiency virus (HIV) positivity, tests positive for HIV, or has congenital or acquired immunodeficiency;
  16. Subject has or has had active TB, suspected extra-pulmonary TB, a history of incompletely treated TB, or latent TB or other latent infection. Subjects with latent TB (clinical findings, purified protein derivative [PPD] or interferon gamma release assay [IGRA]) may be included in the study if prophylactic therapy for latent TB is started at least 4 weeks prior to Screening. Subjects with a potentially untreated other infection (clinical findings) are to be excluded.
  17. Subject has bacterial infections requiring treatment with oral or parenteral antibiotics, within 2 and 4 weeks, respectively.
  18. Subject has a history of systemic opportunistic infection or recurrent infections
  19. Subject has malignancy or history of malignancy, except for adequately treated basal cell skin cancer or adequately treated carcinoma in-situ of the cervix without recurrence at least 5 years.
  20. Subject who received a bacille Calmette-Guérin (BCG) vaccine within 6 months of randomization or live vaccination (e.g., measles, mumps, rubella [MMR]; herpes zoster; varicella, intranasal influenza; and oral poliomyelitis) within 4 weeks of randomization.
  21. Subject with a history of or active substance abuse.
  22. Subject has other severe acute or chronic medical or psychiatric condition or laboratory abnormality.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Czechia,   Hungary,   Poland,   Romania,   Russian Federation,   Serbia,   United States
Removed Location Countries Czech Republic,   Puerto Rico
 
Administrative Information
NCT Number  ICMJE NCT02647866
Other Study ID Numbers  ICMJE 4083-002
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE
Plan to Share IPD: No
Responsible Party Kyowa Kirin, Inc.
Study Sponsor  ICMJE Kyowa Kirin, Inc.
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director: Vincent Strout, MBA Kyowa Kirin, Inc.
PRS Account Kyowa Kirin, Inc.
Verification Date February 2020

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP